Capmatinib Hydrochloride

盐酸卡马替尼

Report date: 2026/04/15 20:02:38
NME

Base Information

Drug NameCapmatinib Hydrochloride
Drug Alias Name卡马替尼Capmatinib hydrochlorideCapmatinibum卡玛替尼Tabrecta +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitors
TargetsHepatocyte growth factor receptor
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisKidney Neoplasms +[22] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryUnited States
Original Approved Date2020/05/06
Country/TerritoryMainland China(BOAO LECHENG)CzechiaBelgium +[41] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesIncyte CorpNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesInstitut National De La Santé Et De La Recherche Médicale, France U979Novartis Pharma Produktions GmbhNovartis Pharma Ag +[9] 
Inactive CompaniesThe University Of California DavisIncyte CorpFountain Medical (Tianjin) Co Ltd
Active IndicationsSolid tumoursKidney NeoplasmsCarcinoma, Non-Small-Cell Lung +[15] 
Inactive IndicationsNeoplasm MetastasisTriple Negative Breast NeoplasmsSquamous Cell Carcinoma of Head and Neck +[7] 

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG